JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT05733390
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05734066
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Stanford Children's Health, Palo Alto, California, United States
🇺🇸Corewell Health, Grand Rapids, Michigan, United States
A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05720494
- Locations
- 🇺🇸
Clinical Site 1, Salt Lake City, Utah, United States
A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT05651152
- Locations
- 🇺🇸
Clinical Site 1, Eatontown, New Jersey, United States
🇺🇸Clinical Site 2, New York, New York, United States
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT05642442
- Locations
- 🇺🇸
Keck School of Medicine of University of Southern California (USC), Los Angeles, California, United States
🇺🇸Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸NeuroTrials Research Inc., Atlanta, Georgia, United States
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT05631327
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸SCRI HealthOne, Denver, Colorado, United States
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 332
- Registration Number
- NCT05557045
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
- Conditions
- Interventions
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05485831
- Locations
- 🇮🇹
Policlinico Sant'Orsola di Bologna, Bologna, Italy
🇮🇹NPI AOU Mater Domini Università Magna Graecia, Catanzaro, Italy
🇮🇹Università degli studi "G. D'annunzio" Chieti, Chieti, Italy
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT05288283
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Dell's Children's Hospital, Austin, Texas, United States
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 282
- Registration Number
- NCT05178316
- Locations
- 🇺🇸
Clinical Innovations Inc., Santa Ana, California, United States
🇺🇸Global Medical Institutes, LLC: Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸Richmond Behavioral Associates, Staten Island, New York, United States